Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Edward T. Zito"'
Autor:
Kathrin U. Jansen, Peter Richmond, Barry N. Kreiswirth, William C. Gruber, Michael D. Nissen, Helen Marshall, Joseph Eiden, Annaliesa S. Anderson, C. Hal Jones, Joseph M. Severs, Edward T. Zito, James Baber, Sepehr Shakib
Publikováno v:
Journal of Infection. 79:582-592
Objectives Assess Staphylococcus aureus (S. aureus) colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine (SA3Ag). Methods In this phase 1, double-blind, sponsor-unblinded study, participants were randomiz
Autor:
Edward T. Zito, David K. C. Cooper, Alejandra Gurtman, David J. Seiden, William C. Gruber, Elizabeth Begier, Joseph Eiden, Annaliesa S. Anderson, Michael Patton, Joseph M. Severs, Kathrin U. Jansen
Publikováno v:
Vaccine. 35:1132-1139
Staphylococcus aureus is a leading cause of healthcare-associated infections. No preventive vaccine is currently licensed. SA4Ag is an investigational 4-antigen S. aureus vaccine, composed of capsular polysaccharide conjugates of serotypes 5 and 8 (C
Autor:
Douglas Girgenti, Joseph M. Severs, Shite Sebastian, Kathrin U. Jansen, James Baber, Jasdeep Singh Nanra, David J. Seiden, Annaliesa S. Anderson, Martin K. Kankam, Robert W. Frenck, Eric Sheldon, William C. Gruber, Robin Hubler, Edward T. Zito, C. Buddy Creech, Joseph Eiden
Publikováno v:
Vaccine. 35:375-384
Background A prophylactic Staphylococcus aureus four-antigen vaccine (SA4Ag) is under development for prevention of invasive S. aureus disease. A preliminary S. aureus three-antigen vaccine (SA3Ag) was reformulated to include a novel manganese transp
Autor:
Douglas Girgenti, Kathrin U. Jansen, David A. Cooper, Edward T. Zito, William C. Gruber, Eric Sheldon, Immermann Frederick, C. Buddy Creech, Robert W. Frenck, Joseph Eiden, Joseph M. Severs, James Baber, Lisa K. McNeil, Annaliesa S. Anderson, Martin K. Kankam, David J. Seiden
Publikováno v:
Vaccine. 35:385-394
Background The decline in immune function with age is a challenge to vaccine development. Following an initial study in adults aged 18–64 years, this study evaluated the safety and immunogenicity of Staphylococcus aureus (S. aureus) 4-antigen (SA4A
Autor:
Annaliesa S. Anderson, Kathrin U. Jansen, David A. Cooper, Douglas Girgenti, Emilio A. Emini, Edward T. Zito, David J. Seiden, Robert W. Frenck, James Baber, Joseph M. Severs, William C. Gruber, Eric Sheldon, C. Buddy Creech, Joseph Eiden, Martin K. Kankam
Publikováno v:
Open Forum Infectious Diseases. 2
Publikováno v:
The Pediatric Infectious Disease Journal. 17:913-918
AIM: To determine whether an oral tetravalent rotavirus vaccine (RV-TV) can be safely coadministered with a combined diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine (DTP/Hib) and oral poliovirus vaccine (OPV) to healthy infants wit
Autor:
Richard L. Ward, Ginger Goldberg, Edward T. Zito, Donna S. Sander, Amy M. Dinsmore, Ruth Rappaport
Publikováno v:
The Pediatric Infectious Disease Journal. 17:386-390
The tetravalent rhesus rotavirus vaccine (RV-TV) has been administered to several thousand children in multiple settings throughout the world. It has been proved safe and efficacious, resulting in an application for licensure in 1997. However, only l
Autor:
Michael E. Mack, Richard L. Ward, Edward T. Zito, Ruth Rappaport, Douglas R. Knowlton, Bruce Davidson
Publikováno v:
The Journal of Infectious Diseases. 176:570-577
The correlation of antibody responses (serum rotavirus IgA and neutralizing antibody to serotype G1-G4 human rotaviruses and rhesus rotavirus [RRV]) in a reassortant rotavirus vaccine trial with protection against rotavirus infection or disease was i
Autor:
George C. Rodgers, Edward T. Zito, Richard L. Ward, Michael E. Mack, Penelope H. Dennehy, Alison J. Markwick
Publikováno v:
The Pediatric Infectious Disease Journal. 15:1012-1018
ObjectiveTo compare the safety and immunogenicity of two dosages of tetravalent rhesus rotavirus vaccine (RRV-TV) and the effect of age at dosing.MethodsA total of 195 infants were stratified by age into 2 groups, 6 to 12 weeks and 16 to 24 weeks, an
Publikováno v:
Journal of Infectious Diseases. 173:306-313
Interference between oral poliovirus vaccine (DPV) and monovalent (RRV-Sl) and tetravalent (RRV-TV) rhesus-human rotavirus vaccines was evaluated. Serum antibody responses to DPV and rotavirus vaccines and efficacy of rotavirus vaccines were compared